In vitro Marrow Purging with Anti-DR Monoclonal Antibodies and Complement in High Dose Risk ALL
Human DR antigens are histocompatibility antigens close to the Ia murine antigens. In mice, la is not expressed on CFU-S, but is present on more differenciated progenitors CFU-GM and BFU-E (1).
DR is expressed to the membrane of most of the non T lymphoid malignancies (2)- Anti DR Mo Ab could have large clinical indications to treat residual marrow leukemic contamination of such patients with the aim of autologous BMT.
DR is expressed in man on GM-CFC, BFU-E and CFU-GEMM (3) suggesting that in vitro marrow treatment with anti DR monoclonal antibodies could affect haematological reconstitution after marrow transplantation.
KeywordsLymphoid Malignancy Human Bone Marrow Cell Treatment Monoclonal Antibody Human Hematopoietic Progenitor Cell Granulocytic Precursor
- (2).NADLER L.M., RITZ J., GRIFFIN J.D. et al, Diagnosis and treatment of human leukemia and lymphoma utilizing monoclonal antibodies Progress in Hematology 12: 187–226, 1981Google Scholar
- (4).GARTNER S., KAPLAN H.S., Long term culture of human bone marrow cells PNAS 77: 4756, 1980Google Scholar
- (5).REBAI N., MALISSEN B., PIERES M. et al Distinct HLA-DR epitopes and distinct families of HLA DR molecules defined by 15 either anti DR or allo anti Ia K cross reacting with human cells. Eur. J. Immunology 1306, 1983Google Scholar